Compass Therapeutics Inc. (CMPX) Stock Forecast & Price Target
Compass Therapeutics Inc. · NASDAQ
$2.21-0.17 (-7.35%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Compass Therapeutics Inc, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $6.00 to $30.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $14.14 sits 541% above the current $2.21. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Strong Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Compass Therapeutics Inc.
As of Sep, 9 of 9 firms rate CMPX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CMPX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.17 – $-0.11 · 11 analysts · +53% YoY
Next period, 11 analysts expect Compass Therapeutics Inc. to earn $-0.14 a share (range $-0.17 – $-0.11), versus $-0.09 a year earlier. Full-year consensus is $-0.49, growing to $-0.54 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 11 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $22.4M next year.
Top analysts covering Compass Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CMPX.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$12.00+444.2% to target
Overall win rate
55%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #121
Buy
$11.00+398.9% to target
Overall win rate
56%
+ Follow
#3
Li Watsek
Cantor Fitzgerald · Rank #275
Buy
No targeton CMPX
Overall win rate
36%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$24.00+988.4% to target
Overall win rate
34%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #345
Buy
$6.00+172.1% to target
Overall win rate
31%
+ Follow
CMPX stock forecast FAQ
What is CMPX's average 12-month price target?+
The 6 analysts with a live target average $14.14 for Compass Therapeutics Inc. over the next 12 months, ranging from a $30.00 high to a $6.00 low.
Is CMPX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CMPX?+
The Street-high target is $30.00 (D. Boral Capital), and the Street-low is $6.00 (Piper Sandler). The average of all 6 active targets is $14.14.
How many Wall Street analysts cover CMPX?+
9 analysts have an active rating on Compass Therapeutics Inc., and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CMPX?+
Among analysts who currently cover CMPX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $12.00 target.
What is Compass Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.17 – $-0.11) across 11 analysts. Full-year EPS is projected at $-0.49, rising to $-0.54 the following year.
How much revenue is Compass Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $22.4M next year.
Have analysts been upgrading or downgrading CMPX lately?+
As of Sep, 9 of 9 firms rate CMPX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CMPX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
